Eclosion SA logo

Eclosion SA

Europe, Geneve, Switzerland, Geneva

Description

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investor Profile

Eclosion SA has made 16 investments, with 0 in the past 12 months and 56% as lead.

Stage Focus

  • Seed (69%)
  • Series C (13%)
  • Post Ipo Equity (6%)
  • Convertible Note (6%)
  • Series Unknown (6%)

Country Focus

  • Switzerland (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Life Science
  • Therapeutics
  • Consulting
  • Genetics
  • Business Development
  • Funding Platform
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Eclosion SA frequently co-invest with?

BioMedPartners
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 1
Edmond de Rothschild Private Equity
Europe, Ile-de-France, France, Paris
Co-Investments: 1
VI Partners
Europe, Schwyz, Switzerland, Altendorf
Co-Investments: 1
FD
Europe, Geneve, Switzerland, Plan-les-ouates
Co-Investments: 1
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 3
Neomed Management
Europe, Oslo, Norway, Oslo
Co-Investments: 1
Vesalius Biocapital Partners
Europe, Luxembourg, Luxembourg, Strassen
Co-Investments: 3
MP Healthcare Venture Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
M Ventures
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1

What are some of recent deals done by Eclosion SA?

MPC Therapeutics

Plan-les-ouates, Geneve, Switzerland

MPC Therapeutics develops a class of compounds with applications in immunotherapy and metabolic diseases.

BiotechnologyHealth CareMedical
Convertible NoteApr 1, 2019
Amount Raised: $220,143
KYLYS

Plan-les-ouates, Geneve, Switzerland

KYLYS provides people and patients with highly effective and safe products based on biomolecules.

BiotechnologyLife ScienceMedicalPharmaceutical
SeedJan 1, 2018
Genkyotex

Geneva, Geneve, Switzerland

Genkyotex develops innovative drugs to block the NOX enzymes that produce oxygen radicals.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityJan 7, 2015
Amount Raised: $19,742,206
Chord Therapeutics

Geneva, Geneve, Switzerland

Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases.

BiotechnologyPharmaceutical
SeedJan 1, 2015
ID-GENE ecodiagnostics

Geneva, Geneve, Switzerland

ID-GENE provides fast, sensitive, and reliable genetic tests for environmental bioassessment and biomonitoring.

BiotechnologyConsultingGenetics
SeedJan 1, 2015
DermAbiotech

Plan-les-ouates, Geneve, Switzerland

DermAbiotech develops innovative targeted therapies for acute T cell-mediated inflammatory diseases.

BiotechnologyTherapeutics
SeedJan 1, 2015
EspeRare

Plan-les-ouates, Geneve, Switzerland

Advancing treatments for rare diseases Together

BiotechnologyLife ScienceNon ProfitPharmaceutical
SeedJan 1, 2014
Geneva Biotech Center

Geneva, Geneve, Switzerland

Geneva Biotech Center responds to the growing trend of pharmaceutical companies outsourcing research and development capabilities.

BiotechnologyHealth CareLife SciencePharmaceutical
SeedJan 1, 2014
Calypso Biotech

Plan-les-ouates, Geneve, Switzerland

Calypso Biotech's vision is to give new hope to patients suffering from severe gastro-intestinal diseases.

BiotechnologyMedicalPharmaceutical
SeedMar 5, 2013
Amount Raised: $3,262,515
ObsEva

Plan-les-ouates, Geneve, Switzerland

ObsEva is a speciality biopharmaceutical company developing drugs for women’s reproductive medicine.

BiotechnologyPharmaceuticalTherapeuticsWomen's
SeedJan 1, 2013